Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hip stem under surveillance: how well does it last?

NCT ID NCT06012656

Disease control Sponsor: Medacta International SA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 100 people who need a hip replacement to see how long the MiniMAX hip stem lasts and how well it works. Participants receive the stem during surgery and are checked for implant survival and hip function using the Harris Hip Score. The goal is to confirm the stem's safety and performance in real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

Jan 2019

Expected to finish

Jan 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The sample size of 100 patients has been defined based on the literature data to guarantee a sufficient number of patients for the evaluation of the performance of the prosthesis, taking into account a 10% of lost patients (dead or lost at follow-up).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient with a clinical condition requiring THA 2. Patient receiving a MiniMAX® stem 3. Patient aged more than 18 years 4. Patient having a Social Insurance or a similar protection regime 5. Patient eligible for an AMIS procedure 6. Patient able to follow the study requirements 7. Patients who are willing to give informed written consent Exclusion Criteria: 1. Patient with local or systemic infection 2. Participation to biomedical research 3. Patient whose BMI exceeds 40 4. Patient with less than 18 years 5. Protected adults 6. Vulnerable person according to article L1121-6 of the Code de la Santè Publique. 7. Pregnant or lactating woman 8. Patient unable to express his/ her opinion about the participation to the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Avascular necrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

arthritic joint disease avascular necrosis bone fracture developmental dysplasia of the hip femoral neck fracture Hip Dislocation, Congenital osteoarthritis osteonecrosis rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Avascular necrosis Congenital hip dysplasia Fracture; femur, head Primary osteoarthritis Rheumatoid arthritis Secondary osteoarthritis Traumatic arthritis

Contacts and locations

Locations

  • Centre Clinical Angouleme Soyaux

    Soyaux, France, 16800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.